Shares in biotechnology company Mesoblast (MSB) were slammed yesterday after a key research partner walked away from research work underway into a treatment for chronic heart failure. Analysts said it was the second bit of negative news for Mesoblast’s main research program
Mesoblast (MSB) was the day’s hot stock yesterday with the shares leaping more than 24% after it became known that US global biotech, Celgene has picked up a 4.7% stake in the Australian company and was looking for closer co-operation.
Mesoblast (MSB) will launch a stem cell therapy for acute graft-versus-host disease (GvHD) in 2016. Baillieu Holst believes clinical success in the upcoming trials, and subsequent US Food & Drug Administration approval, have potential to usher in a boom in regenerative medicine as US investors realise the early scientific promise of stem cells is translating into clinical and commercial reality. This development has now transcended the ethical issues associated with embryonic stem cells.
Data subsets re-released from the trial examining MPC use in intervertebral disc repair were largely negative. On some measure of pain relief the trial did reach statistical significance but not the anatomical improvement measure.
Data subsets re-released from the trial examining MPC use in intervertebral disc repair were largely negative. One some measure of pain relief the trial did reach statistical significance but not the anatomical improvement measure.
Mesoblast has acquired the Osiris Therapeutics stem cell business in the US. The broker had previously though Meso’s Mesenchymal Precursor stem cells offered greater efficacy and manufacturing scalability than Osiris’ more heterogeneous offering, but then both do offer benefits, the broker concedes. The broker thus sees the benefits of having a wider opportunity for success across different diseases but wonders if management isn’t spreading itself a bit thin with this acquisition.